Search
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon. … It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.
Categories: Vitamin B ComplexInotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Ariboflavinosis
go.drugbank.com/conditions/DBCOND0020583Drugs: RiboflavinSynonyms: Vitamin deficiency: [B-complex deficiency NOS] or [ariboflavinosis] or [B12 nutritional deficiency NOS]Menkes Disease
go.drugbank.com/conditions/DBCOND0042586Drugs: Copper histidinateSynonyms: Copper transport disease, X-linked copper deficiencyChronic cutaneous lupus erythematosus
go.drugbank.com/conditions/DBCOND0013492Drugs: Betamethasone · Betamethasone phosphate · Bupivacaine · Chloroquine · Dexamethasone · Flumethasone +4 moreProtokylol
go.drugbank.com/drugs/DB06814ApprovedVet approvedProtokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.
Dexketoprofen
go.drugbank.com/drugs/DB09214ApprovedInvestigationalWithdrawnIt is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties [L1298].
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalIt is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.